Type 2 diabetes and clinical trials

Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.

Uazman Alam and colleagues interrogate current evidence and real-world clinical scenarios to address whether enough is being done with the tools available to screen and diagnose diabetic neuropathy.

Pereira MJ et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0449-6

Nishimura A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0457-6

Board members John Wilding and Pamela Dyson talk about the fresh approach taken to the latest update of the Diabetes UK nutrition guidelines (9:43).

The drive to achieve lower HbA1c targets in older patients is not without concern or risk. Our UK Board address concerns highlighted by recent trials and discuss whether current guidelines do enough to mitigate the risks of overtreatment.

Editorial Board member John Wilding highlights the current evidence for the benefits of physical activity across various domains of type 2 diabetes care and prevention, presenting his view of what should be recommended.

Editorial Board member John Wilding examines what real-world data means to today’s clinicians and presents his vision for the future of this type of evidence.